Corporate ActionJul 31, 2026, 04:12 PM
SL Science Registers 1.04M Shares for Resale by Selling Shareholders
AI Summary
SL Science Holding Limited filed an F-1 registration statement for the resale of up to 1,040,000 Ordinary Shares by its Selling Shareholders. These shares include 780,000 currently held and 260,000 issuable upon conversion of preferred shares, following the company's business combination on June 12, 2026, and a PIPE financing. The company, a biomedical firm focused on cellular and gene therapies, will not receive any proceeds from these sales. SL Science is listed on Nasdaq under "SLBT" and operates as an emerging growth and foreign private issuer, also qualifying as a controlled company.
Key Highlights
- SL Science Holding Limited registered up to 1,040,000 Ordinary Shares for resale by Selling Shareholders.
- The resale includes 780,000 Ordinary Shares currently held and 260,000 shares from Preferred Share conversion.
- The lock-up period for these shares expires six months after the Business Combination closing on June 12, 2026.
- The company will not receive any proceeds from the sale of Ordinary Shares by the Selling Shareholders.
- SL Science is an "emerging growth company" and a "foreign private issuer."
- The company qualifies as a "controlled company" due to Mr. William Wang's 59.53% voting power.
- All three product candidates (CD-19 Armed-T Therapy, GDT Cells for pancreatic/brain cancer) are in pre-clinical trials.
- The company is highly dependent on license agreements with CytoArm and JY BioMed.
Price Impact
More from SLBT